FATTY LIVER FOUNDATION MOURNS THE LOSS OF DR. STEPHEN HARRISON, A VISIONARY IN HEPATOLOGY
April 25, 2024; Boise, IDAHO —With profound grief, the Fatty Liver Foundation (FLF) marks the passing of Dr. Stephen Harrison on Tuesday, April 23, a monumental figure in hepatology whose passion and innovation have left an indelible mark on the field.
FLF honors Dr. Stephen Harrison, a passionate educator, decorated veteran, and pioneering researcher. His multifaced career demonstrated an extraordinary dedication to service, spanning both his role as a Colonel in the U.S. Army and his academic pursuits as a Visiting Professor at the University of Oxford. Dr. Harrison’s visionary approach and collaborative spirit profoundly influenced hepatology, leading to pivotal research at Summit Clinical Research and Pinnacle Clinical Research. His leadership and efforts were instrumental in developing and delivering the first U.S. Food and Drug Administration (FDA) approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), offering new hope and therapeutic options to MASH patients.
“Dr. Harrison was a beacon of excellence in our community, consistently leading with a blend of scientific brilliance and deep commitment to those we serve,” shared Wayne Eskridge, CEO and Co-Founder of FLF. “The news of his passing is a significant loss, and his insights and leadership will be sorely missed.”
“Our community has lost an incredible leader, mentor, and friend in Dr. Stephen Harrison,” stated Henry E. Chang, Executive Director of FLF. “At FLF, we were privileged to collaborate closely with Dr. Harrison and his team at Summit Clinical Research, focusing our joint efforts on ensuring that patients receive the essential services needed to address the social determinants of health.”
FLF extends its sincerest condolences to Dr. Harrison’s family and colleagues as we come to terms with this tragic loss. His pioneering contributions have changed the course of liver disease, and his memory will live on in every life saved and improved through his work. In his honor, FLF pledge to continue the quest for advancements in hepatology with the determination and compassion that Dr. Harrison exemplified throughout his life.
About the Fatty Liver Foundation
The Fatty Liver Foundation (FLF) is a non-profit patient organization committed to enhancing the health and well-being of individuals living with various forms of steatotic liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). FLF is dedicated to improving outcomes of both asymptomatic and diagnosed individuals amid the growing epidemic of SLD through initiatives focused on awareness, screening, education, and patient outreach. FLF extends its support to those living with metabolic dysfunction-associated and alcohol-associated liver disease (MetALD) through its impact program, Sober Livers, ensuring a comprehensive approach to liver health. Connect with us on www.fattyliverfoundation.org, Facebook (Fatty Liver Foundation JUST LIVER NEWS), X (@LiverSaver), and YouTube (@Fatty Liver Foundation).
About Sober Livers
Sober Livers' mission is to empower individuals diagnosed with alcohol-associated liver diseases (ALDs) and those who have had a transplant due to alcohol, by supporting them in discovering and embracing their personalized alcohol recovery journey, while offering guidance through the complexities of managing their liver condition. Connect with us on www.soberlivers.org, Facebook (Sober Livers), X (@SoberLivers), and YouTube (@Sober Livers).
Media Contact
Henry E. Chang
Mobile +1 917-400-8900
# # #
